Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA
Journal of Psychopharmacology May 20, 2006 Jiansong Yang, Masoud Jamei, Amir Heydari et al. 89 citations
A physiologically-based model of drug metabolism predicted that a typical recreational dose of MDMA (ecstasy) inactivates most hepatic CYP2D6 within an hour, and that recovery to basal CYP2D6 levels takes at least 10 days. The analysis suggests that genetic polymorphism of CYP2D6 and coadministration of CYP2D6 inhibitors may have less impact on MDMA's pharmacokinetics and acute toxicity risk than previously thought, consistent with clinical observations showing no obvious link between inherited CYP2D6 deficiency and acute MDMA intoxication.